Plato/W3Networks
Tag: JUST
Breaking News
Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 – Best Contract Research Organization in APAC
 |
Avance Clinical has undergone significant expansion in recent years, including new offices in Sydney and Melbourne to accommodate the growing clinical team in Australia.
The award winner will be announced on 1 September 2022. The finalists are:
- Avance Clinical
- Calyx
- CMIC Group
- EPS
- ICON
- Parexel
- Syneos Health
Avance Clinical's CEO Yvonne Lungershausen said:
"Avance Clinical is extremely pleased to be selected as a finalist for this prestigious award. It is a credit to our amazing customer-focused team for delivering the CRO excellence that has been recognized by the Informa Pharma Intelligence award judges.
"Avance Clinical has a global reputation for agile clinical solutions to support accelerated clinical development for our international biotech clients. We are very proud of our growth and success in APAC in recent years."
According to Informa Pharma Intelligence:
This Award is to recognize CROs that provide full or specialist services to their clients and which have an office in either in Japan or the Asia region including Australia.
Judging considers the quality of services and relationships built with clients and pays particular attention to the innovative patient recruitment strategies the CRO has brought to the table.
The award is based on achievements in the 2021 calendar year.
Core areas judged include:
- The particular capabilities and strengths the CRO offers
- How the company has delivered results that exceed sponsor expectations
- Innovations in patient recruitment strategy has the CRO brought to its partner
- How it has improved its performance, for example, in its quality of data, timelines and transparency
- The steps the company is taking towards streamlining data collection and reporting
To find out more please visit: https://pharmaintelligence.informa.com/events/awards/japan-awards-2022/shortlist-2022
Avance Clinical recently secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m.
"With the support of Riverside and its powerful global footprint and deep healthcare experience, Avance Clinical will execute on its regional and international expansion plans organically and via acquisitions," said Lungershausen.
Avance Clinical is the Australian-owned CRO that provides global regulatory standard clinical research services across all phases to the local and international biopharma industry.
The company is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) which has allowed it to expand into clinical trials for vaccines and GMO therapies.
"We have shown, with our high growth and industry-leading repeat business rates that our focus on gold standard technology paired with solution-orientated clinical experts is the mix our biopharma clients require in this fast-moving, competitive and high-stakes sector," said Lungershausen.
Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.
Find out more:
- Learn about the Australian Advantage here https://www.avancecro.com/the-australian-advantage/
- Read more about Avance Clinical's cell and gene therapy capabilities here www.avancecro.com/avance-clinical-featured-in-endpoints-news-on-cell-gene-therapy-capabilities/
- For more information about the benefits of running your next study with Avance Clinical contact us: enquiries@avancecro.com
About Avance Clinical
Avance Clinical is the largest premium full-service Australian CRO delivering quality clinical trials, with globally accepted data, in Australia and New Zealand for international biotechs. The company's clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.
Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for 24 years.
Pre-clinical through to Phase 1 and 2
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.
With experience across more than 105 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.
Technology
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, and Medrio are just some of the technology partners.
Media Contacts:
Avance Clinical
Chris Thompson
media@avancecro.com
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comAvance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has been selected as a finalist for the Best Contract Research Organization in APAC by Informa Pharma Intelligence.
UREEQA Brings Validation-as-a-Service to the NFT Marketplace
 |
Certainly, any solution will involve validating a creator's identity. However, Ureeqa was conceived of the notion that it was as important to validate the authorship and ownership of every creation as well, a factor lacking in current NFT marketplaces, most of which focus on the ease with which creative pieces can be initialized and sold.
UREEQA's unique platform fixes this by employing its VaaS solution to generate a Package-of-Proof(TM) and a Responsibly Minted(TM) NFT, which come together to serve as evidence that the creator and the creation have been authenticated and are legitimate.
"The initial exchange models were adopted by NFT marketplaces on the fly, hurried and so demand-focused that it enabled bad actors to take advantage of the situation," UREEQA CEO Kirk Fergusson said. "Efforts need to be made to curb the abilities to perpetrate fraud as easily in the first place. Then, we have the answer with a patented process and blockchain-based solution that can be integrated into most NFT platforms."
UREEQA's revolutionary system -- which has been tried and tested by renowned artists on the company's own marketplace -- is a creator-centric hybrid approach to validation and IP protection. The platform's patented validation process enables verification via a centralized model, while generating a Package-of-Proof on the blockchain for anyone to see in decentralized fashion.
Any ETH-based NFT sales platform can integrate the core components of the UREEQA platform into their marketplace, just like that. And so too can any auction house or creator association.
Participating marketplaces can visibly delineate creations that have gone through this thorough assessment process -- highlighting the extra steps that creators have taken to instill confidence amongst prospective purchasers.
"Building scalable world-class NFT marketplaces to address early adopter demand has taken considerable effort over the past year," Fergusson added. "At UREEQA, we've spent the last 18 months building a validation solution designed to support creators first and foremost -- and this patented technology is now available to NFT marketplaces to eradicate fraud and instill trust in the creations they're offering through their platforms. By leveraging our VaaS solution, NFT marketplaces can quickly work to stamp out fraud while preparing their marketplaces for broader mass market adoption."
About UREEQA
Established in Canada in 2020, UREEQA is modernizing the inefficient and bureaucratic systems currently in place for copyright protection. By building a robust and compelling Package-of-Proof(TM) for source creative work, UREEQA only mints Validated NFTs to represent creative rights. This helps keep buyers safe by giving them confidence that the work they are purchasing was minted by the smart contract approved by the creator of the work and is therefore authentic.
The UREEQA platform strives to protect creators' work, their rights and their revenue by harnessing the power of blockchain technology. UREEQA provides value and opportunities for its creators, validators and token holders via URQA, the token at the heart of the UREEQA ecosystem. For more information on UREEQA and upcoming announcements, please visit our website, join our Telegram channel and Discord server, and follow us on Twitter, Instagram and LinkedIn.
- Website: https://www.ureeqa.com/
- Discord: https://discord.com/channels/756566642418384906/824682437417369654
- Instagram: https://www.instagram.com/ureeqa_inc/
- LinkedIn: https://www.linkedin.com/company/ureeqainc/
- Telegram: https://t.me/UREEQA
- Twitter: https://twitter.com/UREEQA_Inc
Disclaimer:
Statements in this article, including any statements relating to UREEQA's future plans and objectives or expected results, may include forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in technology development and commercialization. As a result, actual results may vary materially from those described in the forward-looking statements. Do your own research!
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comUREEQA, a leading digital validation company that helps creators protect, manage and monetize creative work, today announced the launch of its new Validation-as-a-Service (VaaS) solution, designed to tackle NFT fraud and protect NFT creators.
OKLink Insights: OKLink releases the Global Crypto Market 2022/Q1 Report
 |
According to OKLink data, MicroStrategy is by far the largest holder of bitcoin amongst overseas listed companies. It has been hoarding bitcoin since August 2020 and held a total of $5.8 billion worth of 129,218 BTC by the end of the first quarter of 2022, an amount even more than the market capitalization of MicroStrategy itself and three times the position that a certain automobile company held.
For now, Ethereum ecosystem has the most dynamic and viable players of all public blockchains, yet its high Gas fee and network congestion has always been denounced, which results in its decision on moving to 2.0 stage in order to thoroughly solve the congestion on-chain and improve the scalability of the Ethereum blockchain.
Here the core change is the transformation from PoW algorithm to PoS algorithm. And 2022 is a crucial year for Ethereum's plan on 2.0 phase, which could set the stage for Ethereum to become a world-class financial settlement layer and DApp infrastructure.
Staking of ETH is a key step in Ethereum's transition to 2.0. According to OKLink data, more than 10 million ETH have been staked to ETH 2.0 contract. To be more precisely, as of March 31, ETH 2.0 contract has received a total of 10,989,186 ETH, which accounts for 9.3% of total ETH in circulation. This could be a sign that we may soon see an Ethereum that has greatly improved in scalability, security and sustainability.
In addition, several EVM (the core underlying component of Ethereum) based ecology such as Polygon and Fantom rose up to popularity as they promise a lower cost compared to Ethereum
OKLink emphasized in the report that Non-EVM based public blockchains would provide new options for users to move their assets by adding EVM compatibility; besides, this would bring more composability to the global blockchain ecology and accelerate the prosperity of multi-chain era by integrating widely accepted standards.
With the rapid development of global blockchain and crypto market, the processing and analysis of large number of diverse data on blockchains may help in grasping the trend of the crypto market. In this regard, based on self-developed technology platform and rich experience in blockchain data processing and analysis, OKLink has launched a series of data reports reflecting the development of blockchain and crypto industry, and will continue providing support for the development and prosperity of the blockchain industry.
For more information on the Global Crypto Market 2022/Q1 report, please visit:
https://www.oklink.com/academy/zh/hot-oklink-quarterly-insights-q1
About OKLink
As one of the earliest founded blockchain companies in China, OKLink has committed to R&D and commercial application of blockchain technology since its establishment in 2013, and has developed into a world-renowned blockchain technology and data service provider. The company now holds industry leading visual blockchain data processing and analysis tools, integrating big data, AI and other advanced technologies to analyze and process complex and diverse blockchain data.
Media Contact
Norman SUN, OKLink
E: cooperation@oklink.com
U: https://www.oklink.com
Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comOKLink team had just released their Global Crypto Market First Quarter Report 2022 on April 10, which contains a thorough review on the market performance of various public blockchain as well as in-depth discussion of popular fields and topics in the first quarter.
Was ApeCoin just another sophisticated rug-pull? Here’s what metrics seem to suggest
ApeCoin was one of the most hyped news in the second half of March. It was all the rage with Bored Ape Yacht Club owners getting airdropped these coins only to sell them off immediately for basically free money. But few things have come up that suggest ApeCoin might just have been a one-off, the […] Grayscale slams the gavel; AVAX & DOT join the family, SNX & SUSHI cast out
Though crypto is said to be decentralized, Grayscale’s recognition of crypto assets certainly help define the trajectories of coin or token prices. However, more than just new product additions, asset removals are also key in understanding what institutional investors want – or don’t want. No gray area here In a press release, Grayscale Investments shared […] Recent articles
English
Arabic
Bengali
Chinese (Simplified)
Danish
Dutch
Estonian
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Spanish
Swedish
Thai
Turkish
Ukrainian
Urdu
Vietnamese